Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Higher coronary in-stent thromboses and bleeding complications on anti-platelet agents are
more common in Chronic Kidney Disease vs. non-Chronic Kidney Disease patients. Poor
inhibition of platelet aggregation by anti-platelet agents predicts future cardiovascular
events. Clinical practice guidelines are ambiguous about the use of these agents in Chronic
Kidney Disease due to lack of controlled studies. The investigators hypothesize that patients
with Chronic Kidney Disease compared with non-Chronic Kidney Disease have reduced platelet
aggregation and poor platelet inhibitory response to aspirin. The aims are to 1) define the
range of whole blood platelet aggregation in stages 3-5 Chronic Kidney Disease patients; 2)
investigate whether patients with stages 4-5 Chronic Kidney Disease vs. non-Chronic Kidney
Disease have lower platelet aggregation or impaired von Willebrand Factor activity; and 3)
compare inhibition of platelet aggregation from baseline after 2 weeks of aspirin therapy and
another 2 weeks of clopidogrel therapy added to aspirin in Chronic Kidney Disease vs.
non-Chronic Kidney Disease patients. Accomplishing these aims will provide pilot data to
power future studies of targeted anti-platelet agent treatments in Chronic Kidney Disease in
order to improve cardiovascular outcomes.